Loading... Please wait... Loading... Please wait...
| Reporting Date | Major Shareholder Name | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| 05/10/2024 | KEPOS CAPITAL LP | 470,588 | $9,000 | 0.00% | 31.23% |
| 05/15/2024 | NANTAHALA CAPITAL MANAGEMENT, LLC | 235,294 | $4,706 | 0.00% | 15.61% |
| 05/15/2024 | ALTIUM CAPITAL MANAGEMENT LP | 18,823 | $376 | 0.00% | 1.25% |
| 05/13/2024 | UBS GROUP AG | 1,094 | $22 | -91.96% | 0.02% |
| 05/15/2024 | BANK OF AMERICA CORP /DE/ | 582 | $12 | 10.02% | 0.01% |
| 05/07/2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0 | $0 | -100.00% | 0.00% |
| 05/20/2024 | VIRTU FINANCIAL LLC | 0 | $0 | -100.00% | 0.00% |
| 05/15/2024 | ARMISTICE CAPITAL, LLC | 0 | $0 | -100.00% | 0.00% |
A. During the previous two years, 9 institutional investors and hedge funds held shares of TC Biopharm (Holdings) Plc. The most heavily invested institutionals were:
Kepos Capital LP: 470,588
Nantahala Capital Management, LLC: 235,294
Altium Capital Management LP: 18,823
UBS Group AG: 1,094
BANK OF AMERICA CORP /DE/: 582
ARMISTICE CAPITAL, LLC: 0
A. 48.20% of TC Biopharm (Holdings) Plc stock is owned by institutional investors.
A. Institutional investors have bought a total of 3.55 M shares in the last 24 months. This purchase volume represents approximately $47,214 in transactions.
